Chinese trials in first-line NSCLC and colorectal cancer are imminent.
ApexOnco Front Page
Recent articles
Tacti-004 is terminated for futility, and Immutep crashes 89%.
The acquisition of Araris follows a 2023 discovery collaboration.
The company buys Belgium’s EsoBiotec for $425m.
At long last luvelta-T is shelved, and Sutro seeks a new focus.
The Japanese group licenses sapablursen from Ionis for $280m.
Safusidenib could eclipse the recently approved brain cancer drug, Nuvation claims.
Recent first-in-human trials include Pheast and Auron, plus new targets from Immunocore and Cero.
